YOU ARE ABOUT TO EXIT A US HEMANEXT CORPORATE WEBSITE FOR A GLOBAL HEMANEXT ONE PRODUCT WEBSITE

Please be aware that the website you have requested is intended for the residents of countries in the European Union. The site may contain information on products or uses of those products that are not cleared, approved, or otherwise authorized in all countries or regions, including the US Food & Drug Administration.
WITH DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?
Yes No
Hemanext
  • About
    • Executive Team
    • Board of Directors
    • Clinical Advisors
    • Founder
    • Careers
  • Our Science
    • Overview
    • Stored Red Blood Cells
    • Storage Lesion
    • Hypoxic Storage
  • Product
    • Hemanext ONE
    • Technical Documents
    • How to Order
  • Investors
  • Resources
    • News
    • Press Releases
    • Events
      • Blood Drives
    • Educational Symposiums
  • Contact Us
Select Page

Hemanext Welcomes New Member to Board of Directors

Hemanext, News, Press Release

LEXINGTON, Mass., May 21, 2025, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces the appointment of Geoff Crouse, an esteemed professional with over 25 years of leadership in the life sciences sector,...

Hemanext Expands Board of Directors with Two New Members

Hemanext, News, Press Release

LEXINGTON, Mass., May 5th, 2025, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces the appointment of two distinguished professionals to its Board of Directors. Joe Grogan and Phil Pead join the...

Hemanext Announces Close of Series B-2 Equity Funding Round

Hemanext, News, Press Release

LEXINGTON, Mass., January 27, 2025, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces close of series B-2 equity fundraising round. The B-2 fundraising was launched in May 2024 to raise $16-20 million...

Hemanext Inc. Announces First Patients Treated In A Clinical Trial Investigating the Efficacy of the Hemanext ONE® Red Blood Cell Processing and Storage System

Hemanext, News, Press Release

LEXINGTON, Mass., December 20, 2024, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces that the first two patients enrolled have begun receiving transfusions in a multi-center, randomized, controlled cross-over...

Hemanext signs agreement with Hemara Bio, a healthcare distributor in the U.A.E., to provide hospitals and clinicians across the GCC Region with Hemanext ONE® system

Hemanext, News, Press Release

LEXINGTON, Mass., October 29, 2024, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announced that it has entered into an exclusive distribution agreement with Hemara Bio in Dubai, United Arab Emirates (UAE)...

Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.”

Hemanext, News, Press Release

Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.” LEXINGTON, Mass., September 9, 2024, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, marks a...
« Older Entries

Recent Posts

  • Hemanext Welcomes New Member to Board of Directors
  • Hemanext Expands Board of Directors with Two New Members
  • Hemanext Announces Close of Series B-2 Equity Funding Round
  • Hemanext Inc. Announces First Patients Treated In A Clinical Trial Investigating the Efficacy of the Hemanext ONE® Red Blood Cell Processing and Storage System
  • Hemanext signs agreement with Hemara Bio, a healthcare distributor in the U.A.E., to provide hospitals and clinicians across the GCC Region with Hemanext ONE® system

Our Partners

This website may contain information on products or uses of those products that are not authorized in all countries or regions. Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. In Europe Hemanext ONE is CE marked which allows the medical device to be placed in the market in the EEA. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Hemanext, Hemanext ONE, and the logos are registered trademarks of Hemanext, Inc. © 2023 Hemanext, Inc. All rights reserved.
CONTACT US | TERMS OF USE | PRIVACY & COOKIES POLICY
All Rights Reserved. MKTG-0052 Rev BN
  • Facebook
  • Twitter
  • Google
  • Instagram

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content. To learn more, click here. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT